KOTRA INDUSTRIES BERHAD [199901022732 (497632-P)]
QUARTERLY REPORT ON CONSOLIDATED RESULTS
FOR THE FOURTH FINANCIAL QUARTER ENDED 30 JUNE 2026
(The figures have not been audited)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

		Individual Quarter		Cumulative Quarter	
		Current Quarter Ended 30-06-26	**Corresponding Quarter Ended 30-06-25**	**12 Months Cumulative To Date 30-06-26**	**12 Months Cumulative To Date 30-06-25**
	Note	**RM'000**	**RM'000**	**RM'000**	**RM'000**
Revenue		61,039	52,425	233,022	230,784
Operating expenses		(46,761)	(39,755)	(183,709)	(177,777)
Other operating income/(expenses)		1,407	(730)	2,584	(1,624)
Profit from operations		15,685	11,940	51,897	51,383
Finance cost		(190)	(3)	(252)	(27)
Profit before tax		15,495	11,937	51,645	51,356
Tax expense	(B6)	(3,189)	(2,102)	(11,051)	(8,881)
Profit after tax, representing total comprehensive income for the period		12,306	9,835	40,594	42,475
Earnings per share (sen)					
(a) Basic	(B13)	8.30	6.63	27.37	28.64
(b) Diluted	(B13)	8.30	6.63	27.37	28.64

(The Condensed Consolidated Statement of Profit Or Loss And Other Comprehensive Income should be read in conjunction with the Audited Financial Statements for the year ended 30 June 2025 and the accompanying explanatory notes attached to this interim financial report)

KOTRA INDUSTRIES BERHAD [199901022732 (497632-P)]

QUARTERLY REPORT ON CONSOLIDATED RESULTS
FOR THE FOURTH FINANCIAL QUARTER ENDED 30 JUNE 2026
(The figures have not been audited)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	Note	Unaudited As at 30-06-26 RM '000	Audited As at 30-06-25 RM '000
ASSETS			
Non-Current Assets			
Property, plant and equipment		231,545	199,101
Investment properties		1,235	1,261
Right-of-use assets		10,237	10,367
		243,017	210,729
Current Assets			
Derivative assets	(B9)	-	32
Inventories		52,176	51,764
Trade receivables		38,888	32,651
Other receivables, deposits and prepayments		4,261	2,580
Current tax assets		19	10
Fixed deposits with licensed banks		19,407	18,511
Cash and bank balances		16,023	32,176
		130,774	137,724
TOTAL ASSETS		373,791	348,453
EQUITY AND LIABILITIES			
Equity attributable to equity holders of the parent			
Share capital		86,276	86,276
Retained earnings		201,783	193,818
		288,059	280,094
Non-Current Liabilities			
Long-term borrowings	(B8)	22,990	1,531
Lease liabilities		82	82
Deferred tax liabilities		6,952	6,179
Deferred income		67	294
		30,091	8,086
Current Liabilities			
Trade payables		11,853	13,277
Other payables and accruals		37,110	44,125
Derivative liabilities	(B9)	59	-
Lease liabilities		962	960
Current tax liabilities		4,881	1,911
Short-term borrowings	(B8)	776	-
		55,641	60,273
Total Liabilities		85,732	68,359
TOTAL EQUITY AND LIABILITIES		373,791	348,453
Net assets per share attributable to ordinary equity holders of the parent (RM)	(B14)	1.94	1.89

(The Condensed Consolidated Statement of Financial Position should be read in conjunction with the Audited Financial Statements for the year ended 30 June 2025 and the accompanying explanatory notes attached to this interim financial report)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW

	12 Months Ended 30-06-26 RM '000	12 Months Ended 30-06-25 RM '000
Cash Flows From Operating Activities		
Profit before taxation	51,645	51,356
Adjustments for:-		
Reversal of property, plant and equipment written off	-	(1)
Impairment loss on trade receivables	1,706	-
Reversal of impairment loss on trade receivables	-	(345)
Depreciation of property, plant and equipment and investment properties	13,534	12,513
Depreciation of right-of-use assets	1,092	1,092
Fair value changes on derivatives financial instrument	91	(32)
Unrealised (gain)/loss on foreign exchange	(2,328)	211
Inventories written down	1,697	972
Amortisation of deferred income	(227)	(254)
Loss/(Gain) on disposal of property, plant and equipment	18	(2)
Interest expense	252	27
Interest income	(1,557)	(2,285)
Rental income	(19)	(9)
Operating profit before working capital changes	65,904	63,243
(Increase)/Decrease in inventories	(2,109)	1,900
(Increase)/Decrease in receivables	(8,438)	2,635
Decrease in payables	(8,439)	(3,781)
Cash generated from operations	46,918	63,997
Tax paid	(7,375)	(4,367)
Tax refunded	58	70
Net cash from operating activities	39,601	59,700
Cash Flows For Investing Activities		
Interest received	1,557	2,285
Purchase of property, plant and equipment	(45,543)	(38,655)
Rental received	19	9
Proceeds from disposal of property, plant and equipment	26	20
Net cash for investing activities	(43,941)	(36,341)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW (continued)

	12 Months Ended 30-06-26 RM '000	12 Months Ended 30-06-25 RM '000
Cash Flows For Financing Activities		
Dividend paid	(32,629)	(37,820)
Repayment of lease liabilities	(960)	(960)
Drawdown of term loan	22,235	1,531
Interest paid	(705)	(37)
Net cash for financing activities	(12,059)	(37,286)
Net Decrease in Cash & Cash Equivalents	(16,399)	(13,927)
Effect of Exchange Rate Changes on Cash & Cash Equivalents	1,142	(1,399)
Cash & Cash Equivalents at beginning of the financial period	50,687	66,013
Cash & Cash Equivalents at end of the financial period	35,430	50,687
The Cash & Cash Equivalents Comprise The Following:-		
Fixed deposits with licensed banks	19,407	18,511
Cash and bank balances	16,023	32,176
	35,430	50,687

(The Condensed Consolidated Statement of Cash Flow should be read in conjunction with the Audited Financial Statements for the year ended 30 June 2025 and the accompanying explanatory notes attached to this interim financial report)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Share Capital RM '000	Distributable Retained Earnings RM '000	Total RM '000
As at 30 June 2026			
Balance at 1 July 2025	86,276	193,818	280,094
Profit after tax, representing total comprehensive income for the year	-	40,594	40,594
Dividend paid	-	(32,629)	(32,629)
Balance at 30 June 2026	86,276	201,783	288,059
As at 30 June 2025			
As at 1 July 2024	86,276	189,163	275,439
Profit after tax, representing total comprehensive income for the year	-	42,475	42,475
Dividend paid	-	(37,820)	(37,820)
Balance at 30 June 2025	86,276	193,818	280,094

(The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the year ended 30 June 2025 and the accompanying explanatory notes attached to this interim financial report)

A. Explanatory Notes pursuant to MFRS 134 Interim Financial Reporting

A1. Accounting Policies and Methods of Computation

The interim financial statements have been prepared in accordance with MFRS 134, Interim Financial Reporting and paragraph 9.22 of the Bursa Malaysia Securities Berhad Main Market Listing Requirements. The figures for the current quarter of, and cumulative period up to, 30 June 2026 have not been audited. The interim financial statements should be read in conjunction with the audited financial statements of the Group for the financial year ended 30 June 2025.

The material accounting policies adopted by the Group in this interim financial report are consistent with those adopted in the annual audited financial statements for the financial year ended 30 June 2025 except for those mentioned in paragraph A1.1 below.

A1.1 During the current financial period, the Group has adopted the following new Malaysian Financial Reporting Standards and interpretations (including the consequential amendments, if any) which were effective for the financial periods beginning on or after 1 January 2025:-

MFRSs and IC Interpretations (Including The Consequential Amendments)

Amendments to MFRS 121: Lack of Exchangeability

The adoption of the above Malaysian Financial Reporting Standards and/or IC interpretations (including the consequential amendments, if any) did not have any material impact on the Group's financial statements for the period under review.

A1.2 The Group has not applied in advance the following Malaysian Financial Reporting Standards and interpretations (including the consequential amendments, if any) that have been issued by the Malaysian Accounting Standards Board (MASB) but are not yet effective for the current financial period:-

MFRSs and IC Interpretations (Including The Consequential Amendments)	**Effective Date**
MFRS 18 Presentation and Disclosure in Financial Statements	01-Jan-27
MFRS 19 Subsidiaries without Public Accountability: Disclosures	01-Jan-27
MFRS 20 Regulatory Assets and Regulatory Liabilities	01-Jan-29
Amendments to MFRS 9 and MFRS 7: Amendments to the Classification and Measurement of Financial Instruments	01-Jan-26
Amendments to MFRS 9 and MFRS 7: Contracts Referencing Nature-dependent Electricity	01-Jan-26
Amendments to MFRS 10 and MFRS 128: Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	Deferred
Amendments to MFRS 19: Subsidiaries without Public Accountability: Disclosures	01-Jan-27
Amendments to MFRS 121: Translation to a Hyperinflationary Presentation Currency	01-Jan-27
Amendments to MFRS 128: Amendments to the Fair Value Option for Investments in Associates and Joint Ventures	01-Jan-27
Annual Improvements to MFRS Accounting Standards – Volume 11	01-Jan-26

The adoption of the above-mentioned Malaysian Financial Reporting Standards and IC interpretations (including the consequential amendments, if any), insofar as they are applicable to the Group, is expected to have no material impact on the financial statements of the Group upon their initial application.

A2. Seasonal or Cyclical Factors

The business operation of the Group was not materially affected by any seasonal or cyclical factors.

A3. Unusual items affecting Assets, Liabilities, Equity, Net Income or Cash Flows

There were no items affecting the assets, liabilities, equity, net income or cash flows that were unusual because of their nature, size or incidence.

A4. Changes in Estimates

There were no changes in estimates reported in prior interim periods of the current financial year or prior financial years which have a material effect in the current interim period.

A5. Issues, Repurchases and Repayments of Debt and Equity Securities

There were no issues, repurchases or repayments of debt and equity securities, for the period ended 30 June 2026.

A6. Dividend Paid

A second interim single tier dividend of 13.0 sen per ordinary share in respect of the financial year ended 30 June 2025 amounting to RM19,280,831 was paid on 24 October 2025.

An interim single tier dividend of 9.0 sen per ordinary share in respect of the financial year ending 30 June 2026 amounting to RM13,348,267 was paid on 23 April 2026.

A7. Segmental Information

In determining the geographical segments of the Group, sales are based on the country in which the customers are located.

Non-current assets are determined according to the country where these assets are located. The amounts of non-current assets do not include financial instruments and deferred tax assets.

The segment information in respect of the Group's operating segments for the period ended 30 June 2026 is as follows:-

	Revenue Current Quarter Ended 30 Jun		**Revenue 12 Months Ended 30 Jun**		**Non-current assets 12 Months Ended 30 Jun**	
	2026	**2025**	**2026**	**2025**	**2026**	**2025**
	RM'000	**RM'000**	**RM'000**	**RM'000**	**RM'000**	**RM'000**
Malaysia	45,156	40,681	164,194	155,536	243,017	210,729
Overseas	15,883	11,744	68,828	75,248	-	-
	61,039	52,425	233,022	230,784	243,017	210,729

Revenue is recognised at a point in time.

No other segmental information such as segment assets, liabilities and results is presented as the Group is principally engaged in manufacturing and trading of pharmaceutical and healthcare products and operates in Malaysia only.

There is no single customer that contributed 10% or more to the Group's revenue.

A8. Events After the Interim Period

There were no material events after the quarter ended 30 June 2026 and up to 26 August 2026 that have not been reflected in these financial statements.

A9. Effect of Changes in the Composition of the Group

There were no changes in the composition of the Group, including business combinations, acquisition or disposal of subsidiaries and long term investments, restructuring, or discontinuance of operations during the period under review.

A10. Changes in Contingent Liabilities or Contingent Assets

There were no contingent liabilities or contingent assets at the end of this reporting period and end of last financial year.

A11. Capital Commitments

The amount committed for the purchase of property, plant and equipment not provided for in the interim financial statements is as follows:-

	As at 30-06-26 RM'000	**As at 30-06-25 RM'000**
Contracted but not provided for	28,819	47,000

A12. Significant Related Party Transactions

The Group's significant related party transactions for the current financial period ended 30 June 2026 are as follows:-

	Current Quarter Ended 30 Jun		12 Months Ended 30 Jun	
	2026 RM'000	**2025 RM'000**	**2026 RM'000**	**2025 RM'000**
Companies in which certain key management personnel have significant financial interests:				
- Lease payment on short-term leases	2	2	8	8
- Lease payment for right-of-use asset	246	246	984	984
A company in which a close family member of certain key management personnel has significant financial interests:				
- Sales of goods	(115)	(93)	(249)	(295)

The above recurrent transactions were entered into based on normal commercial terms.

B. Explanatory Notes pursuant to Appendix 9B of the Listing Requirements of Bursa Malaysia Securities Berhad

B1. Review of the Performance of the Group

(a) Performance of the current quarter against the preceding year corresponding quarter

	Current Quarter Ended 30 Jun		**Changes**
	2026	**2025**	**%**
	RM'000	**RM'000**	
Turnover	61,039	52,425	16.43%
Profit from operations	15,685	11,940	31.37%
Profit before tax	15,495	11,937	29.81%
Profit after tax (PAT)	12,306	9,835	25.12%
Net PAT margin	20.16%	18.76%	

The Group recorded a 16.43% increase in turnover for the current quarter ended 30 June 2026 compared to the corresponding quarter ended 30 June 2025. This increase was mainly due to higher demand for pharmaceutical products in the local market and supplement products in the export market.

The Group recorded a profit before tax of RM15.50 million for the current quarter ended 30 June 2026, compared to RM11.94 million in the corresponding quarter of the previous year. The increase in profit before tax was primarily attributable to higher sales revenue and a net foreign exchange gain recognised during the current quarter. Further details are set out in Note B12 to this report.

(b) Performance of the current period against the preceding year corresponding period

	12 Months Ended 30 Jun		**Changes**
	2026	**2025**	**%**
	RM'000	**RM'000**	
Turnover	233,022	230,784	0.97%
Profit from operations	51,897	51,383	1.00%
Profit before tax	51,645	51,356	0.56%
Profit after tax (PAT)	40,594	42,475	-4.43%
Net PAT margin	17.42%	18.40%	

The Group recorded a 0.97% increase in turnover for the period ended 30 June 2026, compared to the corresponding 12 months ended 30 June 2025. This marginal increase was mainly due to improved sales performance of pharmaceutical products in the local market, partially offset by lower sales performance of supplement products in the export markets.

The Group recorded a profit before tax of RM51.65 million for the period ended 30 June 2026, compared to RM51.36 million in the corresponding 12 months ended 30 June 2025. The marginal increase was primarily due to a net foreign exchange gain recognised during the current financial year, which was largely offset by higher operating expenses.

B2. Comparison with Preceding Quarter's Results

	Quarter Ended		
	30 Jun 2026 RM'000	**31 Mar 2026 RM'000**	**Changes %**
Turnover	61,039	52,483	16.30%
Profit from operations	15,685	10,884	44.11%
Profit before tax	15,495	10,840	42.94%
Profit after tax (PAT)	12,306	8,097	51.98%
Net PAT margin	20.16%	15.43%	

For the quarter ended 30 June 2026, the Group recorded a 16.30% increase in revenue to RM61.04 million compared to RM52.48 million in the preceding quarter. This quarter-over-quarter increase was primarily driven by stronger sales demand in both the local and export markets for pharmaceutical and health supplement products.

Profit before tax for the current quarter was RM15.50 million, compared to RM10.84 million in the preceding quarter. This increase in profit before tax was primarily attributable to improved sales performance during the period.

B3. Current Year Prospects

With reference to Bank Negara Malaysia's Monetary Policy Statement issued in July 2026, Malaysia's economic outlook remains resilient, supported by sustained domestic demand and stronger-than-expected export performance. Nevertheless, the growth outlook remains subject to downside risks, particularly from prolonged uncertainties surrounding the Middle East conflict, which could fuel domestic inflation and dampen economic growth.

Against this backdrop, the Group views Malaysia’s macroeconomic environment as remaining relatively stable, providing greater predictability over healthcare consumption trends. Nevertheless, the Group remains mindful of external uncertainties, including geopolitical developments and global trade conditions, which may contribute to volatility in export demand, supply chain disruptions and continued upward pressure on operating costs. These factors may continue to exert pressure on operating margins and export performance. While navigating these challenges, the Group remains focused on cost management, operational efficiency, and supply chain resilience. At the same time, driving top-line performance by continuing to manufacture quality generic pharmaceuticals and transitioning towards biopharmaceutical products continue to be the Group's emphasis.

Entering FY2027, the Board remains committed to maintaining a vigilant and prudent approach towards decision-making. Supported by sustained demand for its products, the Group anticipates a positive performance for the financial year ending 30 June 2027. The Board will continue to proactively monitor and review the Group's strategic plans in its pursuit to create sustainable value for shareholders.

B4. Variance of Actual Profit from Forecast Profit or Profit Guarantee

The Group did not issue any profit forecast or profit guarantee in the current quarter or in the prior financial period.

B5. Statement by Directors

The Group did not disclose or announce any profit forecast or projection in a public document in the current quarter or prior financial period.

B6. Breakdown of Tax Expenses

	Quarter Ended 30 Jun		12 Months Ended 30 Jun	
	2026	2025	2026	2025
	RM'000	RM'000	RM'000	RM'000
Income tax:				
- Current tax expense	2,134	1,044	9,869	4,986
- Under/(Over) provision in prior period	-	(56)	409	(409)
Deferred tax:				
- Origination and reversal of temporary differences	861	1,756	579	4,946
- Under/(Over) provision in the previous financial year	194	(642)	194	(642)
Total tax expenses	3,189	2,102	11,051	8,881

The Group's income tax expense is determined based on business profit, interest and rental income. The increase in tax expenses for the period ended 30 June 2026, compared to the corresponding period ended 30 June 2025 was primarily due to tax expense adjustments relating to the prior period and a lower estimated utilisation of tax incentives under double deduction claims.

The effective tax rate for the period under review is lower than the standard tax rate mainly due to the availability of tax incentives on double deduction for eligible expenses provided under the Income Tax Act 1967 and Promotion of Investment Act 1986. The Group recognizes tax liabilities based on prevailing tax laws and approved financial reporting standards on deferred taxation.

B7. Status of Corporate Proposals

There were no corporate proposals announced by the Company as at the date of the issue of this quarterly report.

B8. Details of Group Borrowings and Debt Securities

The Group's borrowings as at the end of this financial period were as follows:-

	As at 30-06-26	As at 30-06-25
	RM'000	RM'000
(a) Short-term Borrowings		
Secured		
Term loans	776	-
(b) Long-term Borrowings		
Secured		
Term loans	22,990	1,531

	Quarter Ended 30 Jun		12 Months Ended 30 Jun	
	2026	2025	2026	2025
	RM'000	RM'000	RM'000	RM'000
(c) Interest Expenses Capitalised	31	10	453	10

The Group capitalised interest expenses that were directly attributable to the construction or acquisition of qualifying property, plant and equipment in accordance with the Group's accounting policy.

B9. Derivative Financial Instruments

(a) Derivative financial instruments are categorised as fair value through profit or loss and measured at their fair value with the changes in fair value recognised in the statement of profit or loss and other comprehensive income at each reporting date. Financial instruments are deployed as risk management tools by the Group and are not used for trading or speculative purposes.

The outstanding Forward Foreign Exchange Contracts as at 30 June 2026 are as follows:-

	Contract Amount RM'000	Fair Value RM'000	
Foreign Exchange Forward Contracts			
- Less than 1 year	2,196	2,255	USD 0.55 million

These forward foreign exchange contracts were entered into to hedge against fluctuations in exchange rates. The settlement of these contracts was in July 2026.

(b) There have been no changes since the end of the previous financial year in respect of the following:-

- the types of derivative financial contracts entered into and the rationale for entering into such contracts, as well as the expected benefits accruing from these contracts;
- the risk management policies in place for mitigating and controlling the risks associated with these financial derivative contracts; and
- the related accounting policies.

B10. Material Litigation

There was no material litigation since the financial period ended 30 June 2026 and up to 26 August 2026.

B11. Dividend Declared

No dividend has been proposed in respect of the current financial period ended 30 June 2026.

B12. Profit before tax

	Quarter Ended 30 Jun		12 Months Ended 30 Jun	
	2026 RM'000	2025 RM'000	2026 RM'000	2025 RM'000
Profit before tax is arrived at after (crediting)/charging:				
Interest income	(247)	(431)	(1,557)	(2,285)
Other income	(312)	(301)	(581)	(713)
Depreciation of property, plant and equipment and investment properties	3,859	3,217	13,534	12,513
Depreciation of right-of-use assets	273	273	1,092	1,092
Amortisation of deferred income	(38)	(62)	(227)	(254)
Rental income	(5)	(9)	(19)	(9)
Reversal of impairment loss on trade receivables	-	(345)	-	(345)
Impairment loss on trade receivables	1,706	-	1,706	-
Loss/(Gain) on disposal of property, plant and equipment	-	-	18	(2)
Reversal of property, plant and equipment written off	-	1	-	(1)
Inventories written down	1,169	606	1,697	972
Foreign exchange loss/(gain):				
- realised	29	679	2,019	4,708
- unrealised	(773)	887	(2,328)	211
Fair value changes on derivatives financial instrument	(60)	(32)	91	(32)

There was no gain or loss on disposal of quoted or unquoted investment or properties nor any exceptional items for the current quarter and financial period ended 30 June 2026.

B13. Earnings Per Share

	Quarter Ended 30 Jun		12 Months Ended 30 Jun	
	2026	**2025**	**2026**	**2025**
(a) Basic Earnings Per Share				
Net Profit attributable to shareholders (RM'000)	12,306	9,835	40,594	42,475
Weighted average number of ordinary shares ('000)	148,314	148,314	148,314	148,314
Basic Earnings per share (sen)	8.30	6.63	27.37	28.64
(b) Diluted Earnings Per Share				
Net Profit attributable to shareholders (RM'000)	12,306	9,835	40,594	42,475
Weighted average number of ordinary shares ('000)	148,314	148,314	148,314	148,314
Diluted Earnings per share (sen)	8.30	6.63	27.37	28.64

B14. Net assets per share

	Unaudited As at 30-06-26	**Audited As at 30-06-25**
Number of ordinary shares issued ('000)	148,314	148,314
Net assets per share attributable to ordinary equity holders of the parent (RM)	1.94	1.89

B15. Audit Report

The auditors' report on the Group's annual financial statements for the year ended 30 June 2025 did not contain any qualification.

BY ORDER OF THE BOARD

CHUA SIEW CHUAN
Secretary

Date : 27 August 2026